STATCenter·
STAT+: Vertex kidney disease drug scrutinized for infection risk
Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.
Read at STAT →
Health · 1 sources covering this
STAT+: Vertex kidney disease drug scrutinized for infection risk
Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/55276908c987ed59d90481573a41b5837923d1a7" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Vertex kidney disease drug scrutinized for infection risk"></iframe>
